Gracell Biotechnologies Inc at Needham Healthcare Conference (Virtual) Transcript

Apr 14, 2022 / 01:30PM GMT
Chang Liu - Needham & Company - Analyst

Welcome to the 21st Needham Healthcare Conference. My name is Chang Liu, and I will be the moderator for this presentation. We welcome Gracell Biotechnologies here today and its Chairman and CEO, William Cao. (Conference Instructions) Without further ado, William, would you like to start your presentation?

William Cao - Gracell Biotechnologies Inc. - Founder, Chairman & CEO

Thank you, Chang. Thanks for having me today. And good morning, everyone. Maybe good evening to someone. Welcome to our presentation. Now let's go to slide 3.

Gracell is a global clinical-stage cell therapy company. Now, we are dedicated to developing breakthrough autologous and allogeneic CAR-T therapies to address major industry challenges in the treatment of cancer, including both hematological cancers and solid tumors. We are well-founded with $288 million in cash, which give us cash runway into 2024.

Next slide, please. Since our funding in 2017, our mission has always been centered on innovation and on fulfilling unmet

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot